Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunotech Biopharm Ltd ( (HK:6978) ) just unveiled an update.
Immunotech Biopharm Ltd reported its unaudited consolidated interim results for the six months ending June 30, 2025, revealing a significant increase in losses compared to the same period in 2024. The company experienced a 39.4% rise in losses before tax, with total comprehensive expenses attributable to owners increasing by 39.5%. Despite a reduction in research and development expenses and administrative costs, the company’s financial position showed a substantial increase in net liabilities, highlighting ongoing financial challenges.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a leading cellular immunotherapy biopharmaceutical company in China, specializing in the research, development, and commercialization of T cell immunotherapy. With nearly 18 years of experience, its core product candidate, EAL®, is a multi-target cellular immunotherapy product that has demonstrated efficacy in treating various types of cancer. The company has developed a proprietary, patented technology platform for producing EAL® cells.
Average Trading Volume: 591,062
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.5B
See more data about 6978 stock on TipRanks’ Stock Analysis page.